Researchers

We conduct research aimed at advancing in-depth basic medical studies and developing new clinical diagnostic medical technologies through the development of biomedical engineering technologies for measuring biosignals, such as brain signals and electromyographic signals, based on wearable and flexible electronics. Our recent research focuses on more efficient biosignal measurement methods and new machine learning-based biosignal processing technologies.

This laboratory has been focusing on clinical epidemiology research and the development of artificial intelligence technologies utilizing South Korea's national health screening data, health insurance claims data, and various structured and unstructured data from medical institutions. We have also carried out projects to measure biomarkers and develop lifestyle management applications using data collected from wearable devices such as smartwatches. Recently, our focus has shifted towards privacy-preserving technologies—such as federated learning—which are essential for the development of AI technologies in the medical field; the advancement of generative AI technologies using knowledge graphs; and causal inference in observational studies through instrumental variable analysis and advanced propensity score matching. Additionally, we possess extensive experience in developing MyData technologies to guarantee healthcare consumers' right to informational self-determination. Currently, we are undertaking a project to develop a chatbot that enables patient-context-based question-and-answering while minimizing hallucinations through the collaboration of knowledge graphs and generative AI. To achieve this, we are working on converting large-scale medical information from healthcare institutions into knowledge graphs. Through this effort, we anticipate not only the successful development of the chatbot, but also the ability to develop AI-based causal inference technologies utilizing artificial intelligence.

Professor Jung Chan Lee conducts research in biomedical engineering, biomechanics, artificial organs, medical device design, and regulatory science. With a background in mechanical engineering and biomedical engineering, his work aims to address unmet clinical needs through engineering principles and medical device development methodologies, with a strong emphasis on translational research. His major research areas include medical devices, artificial intelligence, artificial organs, surgical robotics, hemodialysis, peritoneal dialysis, and biomechanics. He has continuously pursued research on clinically applicable and domestically developed medical technologies, including CRRT systems for critically ill patients, hemodialyzers, and portable and home-based dialysis systems. Based on biomechanical analysis and precision mechanical design, he also develops models that reproduce the physical properties of human tissues and organs and applies them to diagnostic, therapeutic, and educational medical devices. More recently, his research has expanded into medical robotics and AI-based medical devices. Representative examples include robotic CPR systems designed to improve the accuracy and continuity of chest compressions, ultrasound- and biosignal-feedback-based automation technologies, and perception and control technologies for surgical assistance and autonomous surgical robots. In addition, Professor Lee conducts research on AI-based medical devices using medical images, biosignals, and sensor data, as well as regulatory science related to the validation, quality management, and approval strategies of software as a medical device. His research is characterized by a full-cycle approach to medical device development, extending beyond simple prototyping to include engineering design, performance evaluation, preclinical and clinical validation, regulatory strategy, and commercialization. Ultimately, his work aims to improve patient safety, reduce the burden on healthcare p

Prof. Young Bin Choy's laboratory focuses on developing next-generation drug delivery systems based on biocompatible materials and implantable medical devices for the treatment of a wide range of chronic diseases. We engineer diverse drug delivery platforms, including micro- and nanoparticles and hydrogels, to achieve localized and sustained drug release, thereby enhancing therapeutic efficacy while minimizing systemic side effects. In addition, we develop implantable drug delivery devices capable of repeatedly delivering precise doses of therapeutics on demand in response to noninvasive external stimuli, such as mechanical force, magnetic fields, and light. Our platform technologies are being applied to the treatment of cancer, tissue regeneration, diabetes, and other chronic diseases. Through interdisciplinary research spanning fundamental science, preclinical animal studies, clinical translation, and commercialization, we aim to advance innovative therapeutic solutions with real-world clinical impact.